Are Smart Investors Making the Right Decision? DENTSPLY SIRONA Inc. (XRAY)

DENTSPLY SIRONA Inc. (NASDAQ: XRAY) stock fell -4.06% on Tuesday to $35.89 against a previous-day closing price of $37.41. With 2.04 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.29 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $37.19 whereas the lowest price it dropped to was $35.64. The 52-week range on XRAY shows that it touched its highest point at $58.70 and its lowest point at $26.48 during that stretch. It currently has a 1-year price target of $34.91. With its current market cap of 7.64 billion, XRAY has annualized dividend of $0.50 while the current yield stands at 1.39%. Beta for the stock currently stands at 0.93.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XRAY was down-trending over the past week, with a drop of -2.53%, but this was up by 14.55% over a month. Three-month performance surged to 23.50% while six-month performance rose 0.39%. The stock lost -32.19% in the past year, while it has gained 12.72% so far this year. A look at the trailing 12-month EPS for XRAY yields -3.94 with Next year EPS estimates of 1.84. For the next quarter, that number is 0.32. This implies an EPS growth rate of 660.50% for this year and -6.12% for next year. EPS is expected to grow by 3.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -0.80%.

Float and Shares Shorts:

At present, 214.90 million XRAY shares are outstanding with a float of 213.66 million shares on hand for trading. On Oct 13, 2022, short shares totaled 11.93 million, which was 5.54% higher than short shares on Sep 14, 2022. In addition to Mr. Simon D. Campion as the firm’s CEO, Pres & Director, Mr. Glenn G. Coleman serves as its Exec. VP & CFO.

Institutional Ownership:

Through their ownership of 101.59% of XRAY’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 60.62% of XRAY, in contrast to 41.70% held by mutual funds. Shares owned by individuals account for 1.90%. As the largest shareholder in XRAY with 11.10% of the stake, The Vanguard Group, Inc. holds 23,862,982 shares worth 23,862,982. A second-largest stockholder of XRAY, Artisan Partners LP, holds 13,229,926 shares, controlling over 6.16% of the firm’s shares. Nuance Investments LLC is the third largest shareholder in XRAY, holding 12,549,728 shares or 5.84% stake. With a 3.21% stake in XRAY, the First Eagle Global Fund is the largest stakeholder. A total of 6,900,950 shares are owned by the mutual fund manager. The Nuance Mid Cap Value Fund, which owns about 3.10% of XRAY stock, is the second-largest Mutual Fund holder. It holds 6,654,825 shares valued at 211.89 million. Vanguard Total Stock Market Index holds 3.05% of the stake in XRAY, owning 6,550,242 shares worth 208.56 million.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XRAY since 13 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 8 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With XRAY analysts setting a high price target of $40.00 and a low target of $29.00, the average target price over the next 12 months is $34.91. Based on these targets, XRAY could surge 11.45% to reach the target high and fall by -19.2% to reach the target low. Reaching the average price target will result in a decline of -2.73% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. XRAY will report FY 2022 earnings on 02/26/2024. Analysts have provided yearly estimates in a range of $1.98 being high and $1.94 being low. For XRAY, this leads to a yearly average estimate of $1.96. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. DENTSPLY SIRONA Inc. surprised analysts by -$0.11 when it reported $0.41 EPS against a consensus estimate of $0.52. The surprise factor in the prior quarter was $0.05. Based on analyst estimates, the high estimate for the next quarter is $0.35 and the low estimate is $0.30. The average estimate for the next quarter is thus $0.32.


Dividends & Yield:

In terms of dividends, XRAY has a current ratio of $0.5, which is $0.5 over the trailing 12-months, while a dividend of $0.39 is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and XRAY currently yields $1.39. In the past year, XRAY’s dividend yield has been $1.39, but when looking at the stock over the past five years, its yield has been $0.86. Accordingly, XRAY has a current buyback yield of $3.37. This was $3.37 for the TTM, and it was $2.7 for the past five years.

Summary of Insider Activity:

Insiders traded XRAY stock several times over the past three months with 26 Buys and 8 Sells. In these transactions, 1,039,584 shares were bought while 113,251 shares were sold. The number of buy transactions has increased to 81 while that of sell transactions has risen to 37 over the past year. The total number of shares bought during that period was 1,128,301 while 145,405 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *